Cadence, a company specializing in clinical AI for chronic disease management, has successfully closed a $100 million Series C funding round. The investment was led by Spark Capital and included participation from prominent investors like Thrive Capital and General Catalyst. This new capital infusion will fuel the expansion of its AI-powered care model, which is already being adopted by leading health systems nationwide.
Expanding Health System Collaborations
The company recently announced new affiliations with Duke Health and Texas Health Resources, expanding its network to over 20 leading health systems. This growth has enabled Cadence to manage the care of more than 100,000 active patients across the country. As a result of this rapid adoption, the company successfully tripled its annual recurring revenue in the past year.
A Health System's Perspective on Remote Care
Duke Health's partnership underscores the value of continuous remote monitoring in patient care. Dr. Jeffrey Ferranti, Chief Digital Officer at Duke Health, emphasized that crucial health moments often occur at home. By leveraging Cadence, Duke can stay connected to patients, intervene early, and ultimately foster a stronger, more affordable healthcare system for everyone.
Investor Confidence in AI-Powered Healthcare
Will Reed, a new Cadence board member from lead investor Spark Capital, highlighted the company's unique position in the market. He stated that Cadence has already demonstrated significant clinical outcomes and built trust with top health systems. This combination of scale, peer-reviewed results, and economic proof makes it a standout AI care platform poised for major impact.
The Mechanics of Clinical Intelligence
Cadence's platform utilizes supervised AI agents to automate routine aspects of chronic care management. These agents monitor patient vitals daily, identify potential risks early, and facilitate timely interventions like medication adjustments. The system integrates directly into a health system's existing electronic medical records and clinical workflows, extending the capacity of care teams.
Validated Clinical and Financial Outcomes
The effectiveness of Cadence's model is supported by peer-reviewed studies and real-world data. The platform has achieved a 27% reduction in hospital admissions and an annual per-patient cost reduction of $1,302. Furthermore, it has delivered significant clinical improvements, including a 70% relative increase in blood pressure control for hypertension patients.
Vision for Future Growth
With this new capital, Cadence plans to accelerate its expansion across new health systems and enhance its AI capabilities. CEO Chris Altchek explained that the company was built to solve the clinical labor shortage at the core of the chronic disease crisis. The investment provides the necessary infrastructure to scale its proven system from treating 100,000 patients to millions.
This $100 million investment marks a pivotal moment for Cadence, reinforcing its leadership in the clinical AI space. By automating care under clinical supervision, the company is directly addressing the rising costs and workforce constraints associated with chronic disease. The funding will empower Cadence to further its mission of creating a more scalable, efficient, and patient-centric healthcare system.